With the emergence of more digital health technologies in recent years, artificial intelligence (AI) has rapidly expanded in healthcare for a range of applications including handling of administrative logistics at hospitals and other medical facilities, assessment of patient health data, and analysis of novel molecules in drug discovery. AI applications are also helping to provide a better understanding of disease progression, leading to improvements in diagnosis, monitoring, and treatment of specific diseases and conditions. Multiple sclerosis (MS) is one disease area where AI is providing benefit to physicians and patients. Given the unknown cause and the lack of reliable biomarkers, MS presents significant challenges in diagnosis and treatment. Several companies are incorporating AI solutions into their drug development and commercialization strategies to address these challenges.
Beyond the single asset: The rise of combination and synergistic innovation in neurology drug development
Introduction Historically, drug development within the neurology space has been characterized by the search for individual therapies that can arrest complex...